Neuphoria Therapeutics Inc.
4.50%
72,618
1191070
64136E102
Jan 23, 2025
Jan 28, 2025, 04:30 PM
Reporting Persons (5)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Apeiron Investment Group Ltd. | CO | 4.50% | 72,618 | 0 | 72,618 |
| Christian Angermayer | Individual | 4.50% | 72,618 | 0 | 72,618 |
| Apeiron Presight Capital Fund II, L.P. | Partnership | 0.00% | 0 | 0 | 0 |
| Presight Capital Management I, L.L.C. | Other | 0.00% | 0 | 0 | 0 |
| Fabian Hansen | Individual | 0.00% | 0 | 0 | 0 |
Disclosure Items (2)
Common Stock
Neuphoria Therapeutics Inc.
100 Summit Dr, Burlington, MA, 01803
The information contained on the cover pages is incorporated by reference to this Item 5. The information on the cover pages sets forth the aggregate number and percentage of shares of Common Stock outstanding beneficially owned by each of the Reporting Persons, based on 1,628,659 shares of Common Stock outstanding as of December 31, 2024.
The information contained on the cover pages is incorporated by reference to this Item 5. Apeiron is the record holder of the shares of Common Stock reported herein. Christian Angermayer is the majority shareholder of Apeiron and may be deemed to share beneficial ownership of the securities beneficially owned by Apeiron.
On January 24, 2025, Apeiron sold 55,414 shares of Common Stock in an open market transaction on the Nasdaq Global Market at an average price per share of $10.8428. Except for the foregoing, during the past 60 days neither the Reporting Persons nor any Related Person has effected any transactions in the Ordinary Shares.
None.
This Amendment No. 2 is being filed to report that, as of the date hereof, the Reporting Persons do not beneficially own more than five percent of the outstanding Common Stock.